Hey, Takeda shareholders: Shire's Q1 may ease some buyout worries, analysts say

On Thursday, Takeda investors got a closer look at the company they may snag a piece of if the Japanese drugmaker’s $64 billion bid for Shire goes through. And analysts see at least a couple of reasons they should be pleased.